SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
3.770
-0.090 (-2.33%)
Oct 30, 2026, 4:00 PM EDT - Market closed
SCYNEXIS Revenue
SCYNEXIS had revenue of $235.00K in the quarter ending June 30, 2026, a decrease of -82.77%. This brings the company's total for the last twelve months to $17.77M, up 445.46% year-over-year. In the year 2025, SCYNEXIS had annual revenue of $41.20M with 449.95% growth. That makes SCYNEXIS the 34,073rd largest company in the world by revenue and 4,472nd in the United States.
Revenue (ttm)
$17.77M
Revenue Growth
+445.46%
P/S Ratio
1.95
Revenue / Employee
$1,067,556
Employees
18
Market Cap
37.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.20M | 33.71M | 449.95% |
| Dec 31, 2024 | 7.49M | -272.79M | -97.33% |
| Dec 31, 2023 | 280.28M | 270.10M | 2,652.72% |
| Dec 31, 2022 | 10.18M | -16.14M | -61.32% |
| Dec 31, 2021 | 26.33M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -15.60M | -92.55% |
| Dec 31, 2013 | 16.86M | 20.00K | 0.12% |
| Dec 31, 2012 | 16.84M | -9.62M | -36.35% |
| Dec 31, 2011 | 26.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 84.76M |
| Rockwell Medical | 69.39M |
| Aytu BioPharma | 57.57M |
| Cumberland Pharmaceuticals | 44.30M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 3.91M |
| TherapeuticsMD | 3.27M |
| Incannex Healthcare | 12.00K |
SCYX News
- 3 days ago - SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 10 days ago - Scynexis announces topline results from SCY-247 trial - TheFly
- 10 days ago - SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases - GlobeNewsWire
- 10 days ago - SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek - GlobeNewsWire
- 11 days ago - SCYNEXIS Slides: Corporate presentation - Filings
- 26 days ago - Scynexis completes study of SCY-770 - TheFly
- 26 days ago - SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 4 weeks ago - Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program - TheFly